Identified the lungs and liver as major organ sites of CMV

Identified the lungs and liver as major organ sites of CMV latency and recurrence in mice [25] 26]. Induction of IE1 gene expression may be a crucial first step in the reactivation process [27]. A link between CMV reactivation and the increased risk of GVHD has been previously suggested [28]. We now for the first time JW-74 web correlate IE1 gene expression, as indicator for reactivation from latency, with the Tunicamycin custom synthesis severity of pulmonary and hepatic GVHD after murine HCT. CMV latency was established in BALB/c mice by intraperitoneal injection with 36104 PFU of Smith strain MCMV six months prior to subsequent HCT. This time span was chosen in consistence with prior studies [29] 30]. Due to the natural course of CMV infection both in mice and humans, CMV seropositivity is commonly used as a surrogate marker for latent infection, associated with an increased likelihood that seropositive allogeneic HCT recipients reactivate CMV latently present in leukocytes and in target organs. However, the association of either donor or recipient CMV seropositivity with GVHD development is not clearly defined [31] ][][][][][37]. While GVHD and GVHD therapy-related immunosuppression are broadly accepted as risk factors for CMV reactivation, there is conflicting data from retrospective clinical studies on the inverse causal link between CMV reactivation and induction or aggravation of GVHD [11], [31], [38]. CMV infection or reactivation can precede thedevelopment of chronic GVHD and contribute to delayed immune recovery in the post-transplant period [39]. The concept of infections propelling GVHD development is not restricted to CMV, as e.g. Poutsiaka et al. demonstrated that blood stream infections can trigger acute-GHVD complications after HCT [37]. We found, using a murine HCT model that led to donor cell engraftment, that uninfected recipients or those exhibited nonactively replicating virus developed low severity clinical GVHD, whereas recipients with actively replicating MCMV demonstrated more severe GVHD changes in liver and lung. No evidence of CMV disease in these organs was found. CMV reactivation and associated CMV disease play only a limited role in autologous HCT of seropositive patients [40]. This may be explained by a number of reasons including the more rapid immune recovery following transplant, the absence of GVHD, the lacking need for prophylactic or therapeutic immunosuppressive medication and the reinfusion of the recipient’s CMV specific memory B and T cells with the 15755315 transplant inoculum in seropositive patients [41]. Except for the latter, all is true for syngeneic HCT recipients in this study, and all latently CMV infected syngeneic recipients survived without clinical symptoms and differences in pathology between groups. The major immediate early proteins exhibit multiple functions, including pro-inflammatory NF-kappa B activation [17], [42]?[43]. IE1 protein of human and murine CMV exhibit same molecular structure [44]. Earlier studies have reported that MCMV IE1 protein transcripts are not detectable in tissues of latently infected mice [29], while IE1 gene expression has been demonstrated to occur during MCMV infection and has been used as a marker for reactivation from latency in the nontransplant setting [45]. Expression of IE1 gene during MCMV reactivation functions as a strong transcription enhancer in the MCMV genome [46]. In this study, we looked at IE1 gene expression in the context of MCMV reactivation after allogeneic HCT. We found tha.Identified the lungs and liver as major organ sites of CMV latency and recurrence in mice [25] 26]. Induction of IE1 gene expression may be a crucial first step in the reactivation process [27]. A link between CMV reactivation and the increased risk of GVHD has been previously suggested [28]. We now for the first time correlate IE1 gene expression, as indicator for reactivation from latency, with the severity of pulmonary and hepatic GVHD after murine HCT. CMV latency was established in BALB/c mice by intraperitoneal injection with 36104 PFU of Smith strain MCMV six months prior to subsequent HCT. This time span was chosen in consistence with prior studies [29] 30]. Due to the natural course of CMV infection both in mice and humans, CMV seropositivity is commonly used as a surrogate marker for latent infection, associated with an increased likelihood that seropositive allogeneic HCT recipients reactivate CMV latently present in leukocytes and in target organs. However, the association of either donor or recipient CMV seropositivity with GVHD development is not clearly defined [31] ][][][][][37]. While GVHD and GVHD therapy-related immunosuppression are broadly accepted as risk factors for CMV reactivation, there is conflicting data from retrospective clinical studies on the inverse causal link between CMV reactivation and induction or aggravation of GVHD [11], [31], [38]. CMV infection or reactivation can precede thedevelopment of chronic GVHD and contribute to delayed immune recovery in the post-transplant period [39]. The concept of infections propelling GVHD development is not restricted to CMV, as e.g. Poutsiaka et al. demonstrated that blood stream infections can trigger acute-GHVD complications after HCT [37]. We found, using a murine HCT model that led to donor cell engraftment, that uninfected recipients or those exhibited nonactively replicating virus developed low severity clinical GVHD, whereas recipients with actively replicating MCMV demonstrated more severe GVHD changes in liver and lung. No evidence of CMV disease in these organs was found. CMV reactivation and associated CMV disease play only a limited role in autologous HCT of seropositive patients [40]. This may be explained by a number of reasons including the more rapid immune recovery following transplant, the absence of GVHD, the lacking need for prophylactic or therapeutic immunosuppressive medication and the reinfusion of the recipient’s CMV specific memory B and T cells with the 15755315 transplant inoculum in seropositive patients [41]. Except for the latter, all is true for syngeneic HCT recipients in this study, and all latently CMV infected syngeneic recipients survived without clinical symptoms and differences in pathology between groups. The major immediate early proteins exhibit multiple functions, including pro-inflammatory NF-kappa B activation [17], [42]?[43]. IE1 protein of human and murine CMV exhibit same molecular structure [44]. Earlier studies have reported that MCMV IE1 protein transcripts are not detectable in tissues of latently infected mice [29], while IE1 gene expression has been demonstrated to occur during MCMV infection and has been used as a marker for reactivation from latency in the nontransplant setting [45]. Expression of IE1 gene during MCMV reactivation functions as a strong transcription enhancer in the MCMV genome [46]. In this study, we looked at IE1 gene expression in the context of MCMV reactivation after allogeneic HCT. We found tha.